Back to Trades
Buy4
Insight Molecular Diagnostics Inc.
IMDX
Total Value
$652.9K
Net $652.9K bought
Purchases
$652.9K
6 transactions
Company Information
- Company Name
- Insight Molecular Diagnostics Inc.
- Ticker Symbol
- IMDX
- CIK
- 0001642380
Insider Information
- Role
- 10% Owner
- Location
- NEW YORK, NY
10% Owner
Filing Details
- Filing Date
- Apr 20, 2026
- Transaction Date
- Apr 16, 2026
- Accession Number
- 0000919574-26-002306
- Form Type
- 4
- Net Trading Amount
- $652.9K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 16, 2026 | Common Stock, no par value | 102,057 | $3.45 | Purchase | $351.7K |
| Apr 16, 2026 | Common Stock, no par value | — | — | Purchase | — |
| Apr 17, 2026 | Common Stock, no par value | 40,114 | $3.57 | Purchase | $143.3K |
| Apr 17, 2026 | Common Stock, no par value | — | — | Purchase | — |
| Apr 20, 2026 | Common Stock, no par value | 40,690 | $3.88 | Purchase | $158.0K |
| Apr 20, 2026 | Common Stock, no par value | — | — | Purchase | — |
Footnotes
- (F1)The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- (F2)These securities are directly owned by Neal C. Bradsher.
- (F3)This constitutes the weighted average purchase price. The prices range from $3.20 to $3.59. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- (F4)This constitutes the weighted average purchase price. The prices range from $3.45 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- (F5)This constitutes the weighted average purchase price. The prices range from $3.75 to $3.99. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- (F6)These warrants are currently exercisable.